Year None202320222021202020192018 Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor Feb 14, 2023 Read More Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference Feb 06, 2023 Read More Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director Jan 26, 2023 Read More Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium Jan 17, 2023 Read More Pagination First page « Previous page ‹ Page 1 Current page 2
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor Feb 14, 2023 Read More
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference Feb 06, 2023 Read More
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director Jan 26, 2023 Read More
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium Jan 17, 2023 Read More